HBV remains a formidable challenge
Even after decades of ongoing effort, the current standard of care is unable to provide a functional cure for HBV infection1
Our lead therapeutic candidate, ATI-2173, is the only active site polymerase inhibitor nucleotide (ASPIN) in development
Antios has been exploring combination therapy with other complementary drug classes to shut down viral replication and take the first step toward a potential cure for hepatitis B.2,3
ATI-2173 leverages a novel mechanism of action (MOA) to disrupt polymerase activity and shut down viral replication.1
Antios is currently developing ATI-1428 for
the treatment of HBV1
Our CAMs have the potential to synergize with ATI-2173 and target different stages of the HBV life cycle1
Antios was founded in 2018 with the goal of treating and curing HBV.
Learn more about ATI-2173, the first step toward a cure for HBV.
ATI-2173 demonstrated efficacy and safety in phase 2 clinical trials.1
References: 1. Data on file. Antios Therapeutics, Doylestown, PA. 2. Squires KE, Mayers DL, Bluemling GR, et al. ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens. Antimicrob Agents Chemother. 2020;64(9):e00836-20. 3. Mayers DL. ATI-2173: a novel active site polymerase inhibitor nucleotide (ASPIN). Presented at: Hep DART; December 5-9, 2021; Los Cabos, Mexico.